MINDACT long-term results: 70-gene signature MammaPrint to guide adjuvant chemotherapy use in breast cancer

Bookmark and Share
Published: 18 Jun 2020
Views: 1684
Dr Fatima Cardoso - Champalimaud Clinical Center, Lisbon, Portugal

Dr Fatima Cardoso speaks to ecancer about the long-term results from the MINDACT trial that she presented at the virtual ASCO 2020 meeting.

She outlines the background and design of the trial, which is a large prospective trial, investigating the 70-gene signature MammaPrint to guide the use of adjuvant chemotherapy in breast cancer patients.

Dr Cardoso presents the updated results that maintain the clinical utility of this test in this patient population.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.